Objective To observe the clinical efficacy and safety of Hetrombopag combined with cyclosporine in patients with immune thrombocytopenia(ITP).Method This study was a prospective one.71 ITP patients admitted to Anhui Medical University Affiliated Suzhou Hospital from June 2022 to November 2024 were selected as the study objects,the participants were allocated into an observation group(n=35)and a control group(n=36)using the random number table method.The control group received conventional treatment augmented with cyclosporine A(CsA),whereas the observation group was administered Hetrombopag therapy in addition to the control group's treatment regimen.The treatment course of both groups was 4 weeks.Compare the proportions of platelet count(PLT)≥50×109/L,PLT≥30×109/L and PLT reaching 50×109/L at least once in the two groups at the 4th week of treatment,the clinical efficacy after treatment,and the PLT levels before treatment,in the 1st week of treatment,in the 2nd week of treatment and in the 4th week of treatment.The levels of T lymphocyte subsets(CD4+,CD8+,CD4+/CD8+)before treatment and at the 4th week of treatment,as well as the incidence of adverse reactions in both groups.Result At the 4th week of treatment,the proportions of patients with PLT≥50×109/L and PLT reaching 50×109/L at least once in the observation group were both higher than those in the control group,and the difference was statistically significant(P＜0.05).The total clinical effective rate of the observation group after treatment was higher than that of the control group,and the difference was statistically significant(P＜0.05).The results of repeated measures analysis of variance showed that intergroup effect:Compared with the control group,the PLT levels in the observation group were higher at the 1st week,2nd week,and 4th week of treatment,and the difference was statistically significant(P＜0.05).Time effect:Compared with before treatment,the PLT levels of both groups of patients increased at the 1st,2nd,and 4th weeks of treatment,and the difference was statistically significant(P＜0.05).Compared with the first week of treatment,the PLT levels of both groups increased in the second and fourth weeks of treatment,and the PLT level in the fourth week was higher than that in the second week,with statistically significant differences(P＜0.05).Interaction effect:There is an interaction effect between the PLT level intervention plan and time.With the extension of treatment time,the PLT level in the observation group increased more significantly,and the difference was statistically significant(P＜0.05).Compared with before treatment,at the 4th week of treatment,the CD4+levels and CD4+/CD8+values in both groups increased,while the CD8+level decreased,and the differences were statistically significant(P＜0.05).Compared with the control group,the CD4+level in the observation group was higher and the CD8+level was lower at the 4th week of treatment,and the difference was statistically significant(P＜0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups of patients(P＞0.05).Conclusion Hetrombopag combined with CsA has significant effect on ITP patients,can improve the PLT level and effective rate of ITP patients,has the advantages of rapid onset of effect,and can improve immune function,and has high safety.
维普
万方数据